CoChat

Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder

Open access
Gertsik, Lev, Poland, Russell E., Bresee, Catherine, Rapaport, Mark Hyman · 2012 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD). We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response. METHODS: Forty-two subjects participated in this 9-week randomized, masked, placebo-controlled study of combination therapy (two 1 g capsules containing a blend of 900 mg of eicosapentaenoic acid, 200 mg of and docosahexaenoic acid, and 100 mg of other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (two 1 g capsules of olive oil per day plus citalopram) treatment of MDD. RESULTS: The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scale scores over time (F = 7.32; df 1,177; P = 0.008) beginning at week 4 (t = -2.48; df 177; P = 0.014). CONCLUSIONS: Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment; however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e31823f3b5f

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 162

Metadata

Authors
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H.
Affiliations
  • Cedars-Sinai Medical Center (US)
  • Meharry Medical College (US)
Corresponding author
Gertsik, Lev
Venue
Journal of Clinical Psychopharmacology
Published
2012-02
Volume
32
Issue
1
Pages
61-64
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2069184109
Cited by
162
References
37
Citations by year
2025: 5 · 2024: 6 · 2023: 14 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 21 · 2015: 22 · 2014: 10 · 2013: 19 · 2012: 5
FWCI
10.05
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR000124)
  • National Center for Research Resources (U54RR026140, M01RR000425)
  • National Center for Advancing Translational Sciences
  • National Institute on Minority Health and Health Disparities (U54MD007593)
  • National Center for Complementary and Integrative Health (R21AT001077)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
omega-3 fatty acids, citalopram, major depressive disorder, combination therapy, eicosapentaenoic acid, docosahexaenoic acid, selective serotonin reuptake inhibitors, antidepressant response, olive oil placebo
MeSH terms
Adult, Depressive Disorder, Major, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Citalopram, Fatty Acids, Omega-3, Treatment Outcome, Antidepressive Agents, Second-Generation, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e31823f3b5f
The paper
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012). Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31823f3b5f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.